Get the Stockscreener App
2.45
2.51%
0.06
Maravai Lifesciences Holdings Inc stock is traded at $2.45, with a volume of 895.66K.
It is up +2.51% in the last 24 hours and down -3.16% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
See More
Previous Close:
$2.39
Open:
$2.4
24h Volume:
895.66K
Relative Volume:
0.53
Market Cap:
$354.46M
Revenue:
$288.95M
Net Income/Loss:
$-119.03M
P/E Ratio:
-2.7207
EPS:
-0.9005
Net Cash Flow:
$60.67M
1W Performance:
-6.13%
1M Performance:
-3.16%
6M Performance:
-40.39%
1Y Performance:
-72.35%
1-Day Range:
$2.38
$2.505
1-Week Range:
$2.35
$2.71
52-Week Range:
$1.665
$9.60
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
2.45 | 371.82M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Bullish Divergence Spotted in Maravai LifeSciences Holdings Inc. MomentumMarket Activity Summary & Verified Momentum Stock Watchlist - beatles.ru
Is Maravai LifeSciences Holdings Inc. meeting your algorithmic filter criteria2025 EndofYear Setup & Trade Opportunity Analysis Reports - Newser
Risk adjusted return profile for Maravai LifeSciences Holdings Inc. analyzedGap Down & Weekly Watchlist for Hot Stocks - Newser
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2025 Earnings Call Transcript - MSN
Will Maravai LifeSciences Holdings Inc. see short term momentumMarket Movers & AI Enhanced Execution Alerts - Newser
Short interest data insights for Maravai LifeSciences Holdings Inc.July 2025 Analyst Calls & Scalable Portfolio Growth Ideas - Newser
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Holdings Inc. stock trend outlook and recovery pathQuarterly Trade Summary & High Yield Stock Recommendations - Newser
Should you hold or exit Maravai LifeSciences Holdings Inc. nowAnalyst Downgrade & Smart Allocation Stock Tips - Newser
Earnings visualization tools for Maravai LifeSciences Holdings Inc.Weekly Profit Summary & Weekly High Potential Stock Alerts - Newser
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition - MSN
How to forecast Maravai LifeSciences Holdings Inc. trends using time seriesMarket Movers & AI Driven Stock Reports - Newser
Is Maravai LifeSciences Holdings Inc. trending in predictive chart models2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Maravai LifeSciences Holdings Inc. stock daily chart insights2025 Year in Review & Fast Exit and Entry Strategy Plans - Newser
Has Maravai LifeSciences Holdings Inc. found a price floorJuly 2025 Review & Accurate Intraday Trade Tips - Newser
How to use a screener to detect Maravai LifeSciences Holdings Inc. breakouts - Newser
Can you recover from losses in Maravai LifeSciences Holdings Inc.Quarterly Growth Report & Verified Short-Term Trading Plans - Newser
What candlestick patterns are forming on Maravai LifeSciences Holdings Inc.Weekly Market Report & Reliable Price Breakout Signals - Newser
Sentiment analysis tools applied to Maravai LifeSciences Holdings Inc.Recession Risk & Low Drawdown Investment Ideas - Newser
Maravai LifeSciences Announces Restructuring Amid Revenue Decline - TipRanks
Live market analysis of Maravai LifeSciences Holdings Inc.Profit Target & Verified Stock Trade Ideas - Newser
Is Maravai LifeSciences Holdings Inc. Forming a Bottom PatternTrade Entry Summary & Community Trade Idea Sharing Platform - thegnnews.com
Published on: 2025-08-15 03:37:48 - thegnnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Maravai LifeSciences Holdings Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
Maravai LifeSciences (NASDAQ:MRVI) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Acquired by XTX Topco Ltd - Defense World
Maravai Lifesciences Holdings (MRVI) Maintains Buy Rating at RBC Capital with $5.00 Target Price - AInvest
Guggenheim Maintains Hold Rating on Maravai Lifesciences Holdings, Analyst Consensus Sees 85.92% Upside - AInvest
Maravai LifeSciences Announces Cost-Cutting Plan - 富途牛牛
RBC Capital Maintains MRVI Rating, Lowers Price Target | MRVI St - GuruFocus
Maravai LifeScience stock maintains Buy rating at Stifel despite guidance withdrawal - Investing.com Nigeria
Maravai LifeScience stock maintains Buy rating at Stifel despite guidance withdrawal By Investing.com - Investing.com South Africa
Maravai: RBC Capital Keeps Outperform, Cuts PT to $5 from $7. - AInvest
Maravai Lifesciences Announces Major Organizational Restructuring - MSN
Maravai (MRVI) Surges 27% on Restructuring Hopes and Earnings Drama: Is This a Short-Term Bounce or a Structural Turnaround? - AInvest
Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI) - The Globe and Mail
Deutsche Bank Adjusts Maravai Lifesciences Price Target to $4.50 From $5, Maintains Buy Rating - MarketScreener
Maravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026 - MSN
Maravai LifeSciences Q2 2025 Earnings Call Transcript - MarketBeat
Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Maravai Lifesciences Holdings Maintains Buy Rating with $4.25 Price Target - AInvest
Maravai LifeSciences' Q2 2025: Key Contradictions in Revenue Dynamics and Strategic Outlook - AInvest
Maravai LifeSciences: Navigating Restructuring and Strategic Levers for Long-Term Value Creation - AInvest
Maravai LifeSciences Reports $50M Annualized Cost Reduction Plan, Targets Positive EBITDA by 2026 - AInvest
Maravai LifeSciences Holdings, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MRVI) - Seeking Alpha
Transcript : Maravai LifeSciences Holdings, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):